<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02457598</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-401-1757</org_study_id>
    <secondary_id>2015-000834-30</secondary_id>
    <nct_id>NCT02457598</nct_id>
  </id_info>
  <brief_title>Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies</brief_title>
  <official_title>A Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib (ONO/GS-4059) in Combination With Other Targeted Anti-cancer Therapies in Subjects With B-cell Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to evaluate the safety, tolerability,&#xD;
      pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of tirabrutinib&#xD;
      (ONO/GS-4059) in combination with other targeted anti-cancer therapies and to evaluate the&#xD;
      long-term safety of tirabrutinib as a monotherapy and in combination with other targeted&#xD;
      anti-cancer therapies in adults with relapsed or refractory B-cell lymphoproliferative&#xD;
      malignancies.&#xD;
&#xD;
      This study consists of three parts: Dose Escalation, Dose Expansion, and Long-term Safety&#xD;
      Monitoring. During the Dose Escalation phase, participants will be sequentially enrolled in a&#xD;
      standard 3 + 3 dose escalation study design, to receive oral tirabrutinib combined with&#xD;
      idelalisib entospletinib +/- obinutuzumab. The Dose Expansion Phase will enroll additional&#xD;
      participants with a single B-cell lymphoproliferative malignancy disease type to further&#xD;
      evaluate efficacy, safety, tolerability, PK, and pharmacodynamics. The Long-term Safety&#xD;
      Monitoring phase will evaluate the long-term safety of tirabrutinib both as a monotherapy and&#xD;
      in combination with other anti-cancer therapies. As of Amendment 9, all participants&#xD;
      currently on the study who have no clinical evidence of disease progression will transition&#xD;
      into long-term safety monitoring. Participants from the ongoing Study GS-US-401-1787 and&#xD;
      participants who came off Study GS-US-401-1757 and Study GS-US-401-1787 but continued to&#xD;
      receive treatment via named patient use (or individual expanded use) will be enrolled into&#xD;
      the long-term safety monitoring group (Group VI). Participants enrolled in Group VI will&#xD;
      continue the same treatment regimen in Study GS-US-401-1787 or named patient use (or&#xD;
      individual expanded use). As of Protocol Amendment 8, the maximum treatment duration for any&#xD;
      participant is an additional 6 years from the date of this amendment (ie. until November&#xD;
      2025). As of Amendment 9, entospletinib will be provided until 31 December 2020 to&#xD;
      participants who are currently receiving entospletinib. Participants treated with&#xD;
      entospletinib as part of a combination regimen with tirabrutinib will stop receiving&#xD;
      entospletinib by 31 December 2020 but may continue to be treated with tirabrutinib&#xD;
      monotherapy. Idelalisib will be provided as 50 mg tablets until 31 December 2020 and 100 mg&#xD;
      tablets until study completion. Participants assigned to the 50 mg tablet will be given the&#xD;
      option, at the investigator's discretion, to switch to 100 mg once daily idelalisib dose.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 16, 2015</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs) During the Dose Escalation Phase</measure>
    <time_frame>Up to 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate (ORR) at Week 12 During the Dose Expansion Phase for Non-CLL Participants</measure>
    <time_frame>Week 12</time_frame>
    <description>Overall response rate (ORR) is defined as the proportion of participants who achieve a complete response (CR) or partial response (PR) as assessed by disease type.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate (ORR) at Week 24 During the Dose Expansion Phase for CLL Participants</measure>
    <time_frame>Week 24</time_frame>
    <description>Overall response rate (ORR) is defined as the proportion of participants who achieve a complete response (CR) or partial response (PR) as assessed by disease type.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing Treatment-Emergent Adverse Events for the Long-term Safety Phase</measure>
    <time_frame>Up to 6 years from the date of Protocol Amendment 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR) During the Dose Escalation Phase and Dose Expansion Phase</measure>
    <time_frame>Up to 6 years from the date of Protocol Amendment 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) During the Dose Escalation Phase and Dose Expansion Phase</measure>
    <time_frame>Up to 6 years from the date of Protocol Amendment 8</time_frame>
    <description>PFS is defined as the interval from the start of the study therapy to the earlier of the first documentation of definite disease progression or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) During the Dose Escalation Phase and Dose Expansion Phase</measure>
    <time_frame>Up to 6 years from the date of Protocol Amendment 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR) During the Dose Escalation Phase and Dose Expansion Phase</measure>
    <time_frame>Up to 6 years from the date of Protocol Amendment 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For Participants with Chronic Lymphocytic Leukemia (CLL) Only: Proportion of Participants who Achieve Minimal Residual Negative Disease (&lt; 1 leukemia cell/10,000 leukocytes) During the Dose Escalation Phase and Dose Expansion Phase</measure>
    <time_frame>Up to 6 years from the date of Protocol Amendment 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetic (PK) Parameter: AUCtau of tirabrutinib, Idelalisib, Idelalisib Metabolite GS-563117, and Entospletinib During the Dose Escalation Phase and Dose Expansion Phase</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12 (optional), 24 hours postdose</time_frame>
    <description>AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetic (PK) Parameter: Cmax of tirabrutinib, Idelalisib, Idelalisib Metabolite GS-563117, and Entospletinib During the Dose Escalation Phase and Dose Expansion Phase</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12 (optional), 24 hours postdose</time_frame>
    <description>Cmax is defined as the maximum observed concentration of drug.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">376</enrollment>
  <condition>B-cell Malignancies</condition>
  <arm_group>
    <arm_group_label>Tirabrutinib + Idelalisib (Combination I)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation:&#xD;
Participants will receive a single dose of tirabrutinib on Day 1 of Cycle 1 and tirabrutinib 20 mg + idelalisib 50 mg on Day 2 and remainder of Cycle 1. For all subsequent cycles, participants will receive tirabrutinib 20 mg + idelalisib 50 mg. Based on DLTs observed in subsequent cohorts, additional participants will be enrolled and administered escalating dose of tirabrutinib up to 160 mg + idelalisib up to 100 mg to determine the maximum tolerated dose (MTD) of tirabrutinib either once daily or twice daily.&#xD;
Dose Expansion:&#xD;
Additional participants will receive tirabrutinib + idelalisib for an additional 6 years from the date of Protocol Amendment 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tirabrutinib + Entospletinib (Combination II)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation:&#xD;
Participants will receive a single dose of tirabrutinib 40 mg on Day 1 of Cycle 1 and tirabrutinib 40 mg + entospletinib 200 mg on Day 2 and remainder of Cycle 1. For all subsequent cycles, participants will receive tirabrutinib 40 mg + entospletinib 200 mg. Based on DLTs observed in subsequent cohorts, additional participants will be enrolled and administered escalating dose of tirabrutinib up to 160 mg + entospletinib up to 400 mg to determine the maximum tolerated dose (MTD) of tirabrutinib either once daily or twice daily.&#xD;
Dose Expansion:&#xD;
Additional participants will receive tirabrutinib + entospletinib for an additional 6 years from the date of Protocol Amendment 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tirabrutinib + Idelalisib + Obinutuzumab (Combination III)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation:&#xD;
Participants will receive tirabrutinib + idelalisib + obinutuzumab 1000 mg at 8 doses (tirabrutinib and idelalisib doses will depend on results of Combination I data). Based on DLTs observed, additional participants will be enrolled to determine the maximum tolerated dose (MTD) of tirabrutinib either once daily or twice daily.&#xD;
Dose Expansion:&#xD;
Additional participants will receive tirabrutinib + idelalisib + obinutuzumab for an additional 6 years from the date of Protocol Amendment 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tirabrutinib + Entospletinib + Obinutuzumab (Combination IV)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation:&#xD;
Participants will receive tirabrutinib + entospletinib + obinutuzumab 1000 mg at 8 doses (tirabrutinib and entospletinib doses will depend on results of Combination II data). Based on DLTs observed, additional participants will be enrolled to determine the maximum tolerated dose (MTD) of tirabrutinib either once daily or twice daily.&#xD;
Dose Expansion:&#xD;
Additional participants will receive tirabrutinib + idelalisib + obinutuzumab for an additional 6 years from the date of Protocol Amendment 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Agent Tirabrutinib (Combination V)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with relapsed or refractory chronic lymphocytic leukemia (CLL) may be enrolled to receive tirabrutinib 80 mg once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tirabrutinib</intervention_name>
    <description>Capsules or tablets administered orally</description>
    <arm_group_label>Single Agent Tirabrutinib (Combination V)</arm_group_label>
    <arm_group_label>Tirabrutinib + Entospletinib (Combination II)</arm_group_label>
    <arm_group_label>Tirabrutinib + Entospletinib + Obinutuzumab (Combination IV)</arm_group_label>
    <arm_group_label>Tirabrutinib + Idelalisib (Combination I)</arm_group_label>
    <arm_group_label>Tirabrutinib + Idelalisib + Obinutuzumab (Combination III)</arm_group_label>
    <other_name>ONO/GS-4059</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idelalisib</intervention_name>
    <description>Tablets administered orally twice daily</description>
    <arm_group_label>Tirabrutinib + Idelalisib (Combination I)</arm_group_label>
    <arm_group_label>Tirabrutinib + Idelalisib + Obinutuzumab (Combination III)</arm_group_label>
    <other_name>Zydelig®</other_name>
    <other_name>GS-1101</other_name>
    <other_name>CAL-101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entospletinib</intervention_name>
    <description>Tablets administered orally</description>
    <arm_group_label>Tirabrutinib + Entospletinib (Combination II)</arm_group_label>
    <arm_group_label>Tirabrutinib + Entospletinib + Obinutuzumab (Combination IV)</arm_group_label>
    <other_name>GS-9973</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obinutuzumab</intervention_name>
    <description>Administered intravenously</description>
    <arm_group_label>Tirabrutinib + Entospletinib + Obinutuzumab (Combination IV)</arm_group_label>
    <arm_group_label>Tirabrutinib + Idelalisib + Obinutuzumab (Combination III)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of follicular lymphoma (FL), marginal zone lymphoma (MZL), small lymphocytic&#xD;
             lymphoma (SLL), chronic lymphocytic leukemia (CLL) (meeting International Workshop on&#xD;
             Chronic Lymphocytic Leukemia (IWCLL) Criteria 2008), mantle cell lymphoma (MCL),&#xD;
             Waldenstrom's macroglobulinemia (WM), or non-germinal center B-cell lymphoma (GCB)&#xD;
             diffuse large B-cell lymphoma (DLBCL) as documented by medical records on World Health&#xD;
             Organization (WHO) criteria&#xD;
&#xD;
          -  Prior treatment for FL, MZL, SLL, MCL, WM with ≥ 2 or for CLL or non-GCB DLBCL ≥ 1&#xD;
             chemotherapy-based or immunotherapy-based regimen, and not transplant eligible and&#xD;
             have had either progressive disease (PD) or no response to previous treatment&#xD;
&#xD;
          -  For diseases other than Waldenstrom's macroglobulinemia (WM), presence of&#xD;
             radiographically measurable presence of ≥ 1 lesion that measures ≥ 2.0 cm in the&#xD;
             longest dimension (LD) and ≥ 1.0 cm in the longest perpendicular dimension (LPD)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) ≤ 2&#xD;
&#xD;
          -  Platelets ≥ 50 x 10^9/L; Hb ≥ 8.0 g/dL; absolute neutrophil count (ANC) ≥ 1.0 x 10^9/L&#xD;
&#xD;
          -  Without transfusion and growth factors within 7 days&#xD;
&#xD;
          -  Aspartate transaminase/alanine transaminase (AST/ALT) ≤ 2.5 x upper limit of normal&#xD;
             (ULN)&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 x ULN&#xD;
&#xD;
          -  Creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 60 mL/min&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Willingness and ability to comply with protocol-specified Pneumocystis jirovecii&#xD;
             pneumonia (PJP) prophylaxis&#xD;
&#xD;
          -  Long-term Safety Monitoring group only (Group VI):&#xD;
&#xD;
               -  Currently enrolled in Study GS-US-401-1787 or previously enrolled in Study&#xD;
                  GS-US-401-1757 or Study GS-US-401-1787 and currently receiving continued&#xD;
                  treatment via named patient use&#xD;
&#xD;
               -  Continuing to benefit from the current treatment regimen in the opinion of the&#xD;
                  investigator/treating physician&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Hepatitis B surface antigen (HBsAG) positive or hepatitis B core antibody positive&#xD;
&#xD;
          -  Hepatitis C virus (HCV) antibody positive&#xD;
&#xD;
          -  History of long QT syndrome or whose corrected QT(QTc) interval measured (Fridericia&#xD;
             method) at screening is prolonged (&gt;450 ms)&#xD;
&#xD;
          -  Long-term Safety Monitoring group only (Group VI):&#xD;
&#xD;
               -  Evidence of clinical or radiological disease progression&#xD;
&#xD;
        Note: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Health Goshen Center for Cancer Care</name>
      <address>
        <city>Goshen</city>
        <state>Indiana</state>
        <zip>46506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille, Hopital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Haut Leveque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Lyon Sud</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer-Oncopole I.U.C.T-O</name>
      <address>
        <city>Toulouse</city>
        <zip>3110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <zip>CB20QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiff and Vale Health Board, Clinical Research Facility</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds Teaching Hosptials NHS Trust, Dept of Haematology</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Leicester NHS Trust</name>
      <address>
        <city>Leicester</city>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Plymouth Hospitals NHS Trust</name>
      <address>
        <city>Plymouth</city>
        <zip>PL68DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Southampton NHS Foundation Trust</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 27, 2015</study_first_submitted>
  <study_first_submitted_qc>May 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2015</study_first_posted>
  <last_update_submitted>May 28, 2021</last_update_submitted>
  <last_update_submitted_qc>May 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obinutuzumab</mesh_term>
    <mesh_term>Idelalisib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

